| Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia SL Maude, TW Laetsch, J Buechner, S Rives, M Boyer, H Bittencourt, ... New England Journal of Medicine 378 (5), 439-448, 2018 | 4558 | 2018 |
| Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma MA Pule, B Savoldo, GD Myers, C Rossig, HV Russell, G Dotti, MH Huls, ... Nature medicine 14 (11), 1264-1270, 2008 | 1343 | 2008 |
| Antitumor activity and long-term fate of chimeric antigen receptor–positive T cells in patients with neuroblastoma CU Louis, B Savoldo, G Dotti, M Pule, E Yvon, GD Myers, C Rossig, ... Blood, The Journal of the American Society of Hematology 118 (23), 6050-6056, 2011 | 1294 | 2011 |
| Monoculture-derived T lymphocytes specific for multiple viruses expand and produce clinically relevant effects in immunocompromised individuals AM Leen, GD Myers, U Sili, MH Huls, H Weiss, KS Leung, G Carrum, ... Nature medicine 12 (10), 1160-1166, 2006 | 632 | 2006 |
| Cytotoxic T lymphocyte therapy with donor T cells prevents and treats adenovirus and Epstein-Barr virus infections after haploidentical and matched unrelated stem cell … AM Leen, A Christin, GD Myers, H Liu, CR Cruz, PJ Hanley, ... Blood, The Journal of the American Society of Hematology 114 (19), 4283-4292, 2009 | 368 | 2009 |
| Adenovirus infection rates in pediatric recipients of alternate donor allogeneic bone marrow transplants receiving either antithymocyte globulin (ATG) or alemtuzumab (Campath) GD Myers, RA Krance, H Weiss, I Kuehnle, G Demmler, HE Heslop, ... Bone marrow transplantation 36 (11), 1001-1008, 2005 | 140 | 2005 |
| Updated analysis of the efficacy and safety of tisagenlecleucel in pediatric and young adult patients with relapsed/refractory (r/r) acute lymphoblastic leukemia SA Grupp, SL Maude, S Rives, A Baruchel, MW Boyer, H Bittencourt, ... Blood 132, 895, 2018 | 116 | 2018 |
| Three-year update of tisagenlecleucel in pediatric and young adult patients with relapsed/refractory acute lymphoblastic leukemia in the ELIANA trial TW Laetsch, SL Maude, S Rives, H Hiramatsu, H Bittencourt, P Bader, ... Journal of Clinical Oncology 41 (9), 1664, 2023 | 106 | 2023 |
| Disease burden affects outcomes in pediatric and young adult B-cell lymphoblastic leukemia after commercial tisagenlecleucel: a pediatric real-world chimeric antigen receptor … LM Schultz, C Baggott, S Prabhu, HL Pacenta, CL Phillips, J Rossoff, ... Journal of Clinical Oncology 40 (9), 945, 2022 | 106 | 2022 |
| Next-generation sequencing of minimal residual disease for predicting relapse after tisagenlecleucel in children and young adults with acute lymphoblastic leukemia MA Pulsipher, X Han, SL Maude, TW Laetsch, M Qayed, S Rives, ... Blood cancer discovery 3 (1), 66-81, 2022 | 96 | 2022 |
| Global registration trial of efficacy and safety of CTL019 in pediatric and young adult patients with relapsed/refractory (R/R) acute lymphoblastic leukemia (ALL): update to … J Buechner, SA Grupp, SL Maude, M Boyer, H Bittencourt, TW Laetsch, ... Clinical Lymphoma, Myeloma and Leukemia 17, S263-S264, 2017 | 95 | 2017 |
| Patient-reported quality of life after tisagenlecleucel infusion in children and young adults with relapsed or refractory B-cell acute lymphoblastic leukaemia: a global, single … TW Laetsch, GD Myers, A Baruchel, AC Dietz, MA Pulsipher, H Bittencourt, ... The Lancet Oncology 20 (12), 1710-1718, 2019 | 90 | 2019 |
| Analysis of a global registration trial of the efficacy and safety of CTL019 in pediatric and young adults with relapsed/refractory acute lymphoblastic leukemia (ALL) SA Grupp, TW Laetsch, J Buechner, H Bittencourt, SL Maude, ... Blood 128 (22), 221, 2016 | 87 | 2016 |
| Building blocks for institutional preparation of CTL019 delivery J McGuirk, EK Waller, M Qayed, S Abhyankar, S Ericson, P Holman, ... Cytotherapy 19 (9), 1015-1024, 2017 | 83 | 2017 |
| Reconstitution of adenovirus-specific cell-mediated immunity in pediatric patients after hematopoietic stem cell transplantation GD Myers, CM Bollard, MF Wu, H Weiss, CM Rooney, HE Heslop, ... Bone marrow transplantation 39 (11), 677-686, 2007 | 82 | 2007 |
| Adenoviral infections in hematopoietic stem cell transplantation AM Leen, CM Bollard, GD Myers, CM Rooney Biology of Blood and Marrow Transplantation 12 (3), 243-251, 2006 | 68 | 2006 |
| Optimal fludarabine lymphodepletion is associated with improved outcomes after CAR T-cell therapy VA Fabrizio, JJ Boelens, A Mauguen, C Baggott, S Prabhu, E Egeler, ... Blood advances 6 (7), 1961-1968, 2022 | 60 | 2022 |
| Cytomegalovirus (CMV) infections and CMV-specific cellular immune reconstitution following reduced intensity conditioning allogeneic stem cell transplantation with alemtuzumab R Lamba, G Carrum, GD Myers, CM Bollard, RA Krance, HE Heslop, ... Bone marrow transplantation 36 (9), 797-802, 2005 | 55 | 2005 |
| Comparable outcome of alternative donor and matched sibling donor hematopoietic stem cell transplant for children with acute lymphoblastic leukemia in first or second remission … AA Kennedy-Nasser, CM Bollard, GD Myers, KS Leung, S Gottschalk, ... Biology of Blood and Marrow Transplantation 14 (11), 1245-1252, 2008 | 54 | 2008 |
| Perspectives on outpatient administration of CAR-T cell therapy in aggressive B-cell lymphoma and acute lymphoblastic leukemia GD Myers, MR Verneris, A Goy, RT Maziarz Journal for immunotherapy of cancer 9 (4), 2021 | 53 | 2021 |
